UNSPSC 51144203: Nizofenone

This classification denotes a neuroprotective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7A2NOC3R88. European Medicines Agency schedules Nizofenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09336MIG. Nizofenone generally arises in the molecular formula C21H21CLN4O3.

UNSPSC 51144203 Nizofenone is a Commodity code that captures pharmaceutical products and related systems state and local governments procure to support public health and community health initiatives. However, the recent solicitations tagged to this code show minimal direct alignment with nizofenone itself; instead, they reflect procurement of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local issuing bodies pursuing this work include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are the repeat buyers named in recent opportunities. The scope ranges from stand-alone naloxone and drug deactivation system procurement to broader generic pharmaceutical supply agreements through authorized wholesalers and exploratory market-intelligence efforts around direct-to-manufacturer prescription models.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with contracts effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. Vendors pursuing MMCAP contracts must maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, comply with cGMP and DSCSA requirements, and carry $5 million commercial general liability insurance.